Back to results
US 9,314,473 B2Granted
System and method for diagnosis and treatment
AssigneePop Test Oncology Limited Liability Company
InventorsRandice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
Life of this patent
Estimating the term…
Abstract
This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
Claims2
A pharmaceutical composition for treating treatment resistant prostate cancer, comprising:
- a) therapeutically effective amounts of at least one androgen receptor antagonist selected from the group consisting of ARN-509, enzalutamide, ketonazole, abiraterone, abiraterone acetate, orteronel, and combinations thereof;
- b) therapeutically effective amounts of the GCR (glucocorticoid receptor) antagonist ORG 34517;
- and
- c) optionally, at least one pharmaceutically acceptable carrier.
1 more element
A kit for treating treatment resistant prostate cancer comprising:
- (a) therapeutically effective amounts of the GCR (glucocorticoid receptor) antagonist ORG 34517;
- (b) therapeutically effective amounts of at least one androgen receptor antagonist selected from the group consisting of ARN-509, flutamide, enzalutamide, bicalutamide, ketonazole, abiraterone, abiraterone acetate, and combinations thereof;
- (c) optionally, at least one pharmaceutically acceptable carrier;
- and
- (d) at least one blister package;
- a lidded blister;
- a blister card or packet;
- a clamshell;
- an intravenous (IV) package, IV packet or IV container;
- a tray or a shrink wrap comprising the pharmaceutical composition of (a) and instructions for use of the pharmaceutical composition for treating treatment resistant prostate cancer.
7 more elements
Dependencies are inferred from the claim text.